Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Results From the CC-92480-MM-002 Trial

被引：0
|
作者：
Oriol, Albert [1 ,2 ]
Sandhu, Irwindeep [3 ]
Raab, Marc S. [4 ]
White, Darrell [5 ,6 ]
LeBlanc, Richard [7 ]
Raje, Noopur [8 ]
Ocio, Enrique M. [9 ]
Perrot, Aurore [10 ]
Facon, Thierry [11 ]
Rodriguez, Cesar [12 ]
Waesch, Ralph [13 ]
Amatangelo, Michael [14 ]
Zhou, Zehua [14 ]
Wang, Yue [14 ]
Civardi, Tiziana [15 ]
Koo, Phillip [14 ]
Maciag, Paulo [14 ]
Zhu, Daniel [14 ]
Katz, Jessica [14 ]
Richardson, Paul G. [16 ]
机构：
[1] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona, Spain
[2] Hosp Badalona Germans Trias & Pujol, Josep Carreras Inst, Badalona, Spain
[3] Univ Alberta, Edmonton, AB, Canada
[4] Univ Klinikum Heidelberg, Heidelberg, Germany
[5] Dalhousie Univ, Halifax, NS, Canada
[6] Queen Ellizabeth II Hlth Sci Ctr, Halifax, NS, Canada
[7] Univ Montreal, Hop Maisonneuve Rosemont, Montreal, PQ, Canada
[8] Massachusetts Gen Hosp, Boston, MA USA
[9] Hosp Univ Marques de Valdecilla IDIVAL, Santander, Spain
[10] Inst Univ Canc Toulouse Oncopole, Toulouse, France
[11] Univ Lille, Ctr Hosp Univ CHU Lille, Serv Malad Sang, Lille, France
[12] Icahn Sch Med Mt Sinai, New York, NY USA
[13] Univ Freiburg, Dept Med, Med Ctr, Freiburg, Germany
[14] Bristol Myers Squibb, Princeton, NJ USA
[15] Celgene Int Sarl, Boudry, Switzerland
[16] Dana Farber Canc Inst, Boston, MA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MM-520
引用
收藏
页码：S566 / S566
页数：1
相关论文
共 50 条
  • [21] PHASE I TRIAL OF VORINOSTAT PLUS BORTEZOMIB (BORT) IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (MM) PATIENTS (PTS)
    Badros, Z.
    Philip, S.
    Niesvizky, R.
    Goloubeva, O.
    Harris, C.
    Zweibel, J.
    Wright, J.
    Burger, A.
    Baer, M.
    Egorin, M.
    Grant, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 258 - 258
  • [22] Phase I trial of vorinostat plus bortezomib (bort) in relapsed/refractory multiple myeloma (mm) patients (pts)
    Badros, A. Z.
    Philip, S.
    Niesvizk, R.
    Goloubeva, O.
    Harris, C.
    Zweibel, J.
    Wright, J. J.
    Burger, A.
    Baer, M. R.
    Egorin, M. J.
    Grant, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [23] Impact of renal impairment (RI) on pharmacokinetics (PK) and clinical outcomes with mezigdomide plus dexamethasone (DEX) in relapsed/refractory multiple myeloma (RRMM)
    Trudel, Suzanne
    Bahlis, Nizar J.
    Popat, Rakesh
    Mateos, Maria-Victoria
    Vangsted, Annette J.
    Ramasamy, Karthik
    Martinez-Lopez, Joaquin
    Quach, Hang
    Orlowski, Robert Z.
    Burnett, Joseph
    Gaudy, Allison
    Chen, Wencong
    Gong, Jing
    Hadala, Joseph T.
    Donahue, Cynthia
    Koo, Phillip
    Zhu, Yue
    Katz, Jessica
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Results of Study CC-220-MM-001 Dose Expansion of Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients with Relapsed/Relapsed-Refractory Multiple Myeloma (RRMM)
    Knop, S.
    Lonial, S.
    Popat, R.
    Hulin, C.
    Jagannath, S.
    Oriol, A.
    Richardson, P. G.
    Facon, T.
    Weisel, K.
    Larsen, J. T.
    Minnema, M. C.
    Abdallah, A. -O. A.
    Badros, A. Z.
    Stadtmauer, E. A.
    Chen, M.
    Nguyen, T., V
    Amin, A.
    Peluso, T.
    van de Donk, N. W. C. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 247 - 247
  • [25] Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-220-MM-001 Trial
    Lonial, Sagar
    Popat, Rakesh
    Hulin, Cyrille
    Jagannath, Sundar
    Oriol, Albert
    Richardson, Paul G.
    Facon, Thierry
    Weisel, Katja
    Larsen, Jeremy T.
    Minnema, Monique C.
    Abdallah, Al-Ola
    Badros, Ashraf Z.
    Knop, Stefan
    Stadtmauer, Edward A.
    Chen, Min
    Nguyen, Tuong Vi
    Amin, Alpesh
    Kueenburg, Elisabeth
    Peluso, Teresa
    van de Donk, Niels W. C. J.
    BLOOD, 2021, 138
  • [26] Final Results of Phase 1 MMRC Trial of Selinexor, Carfilzomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM)
    Jakubowiak, Andrzej
    Jasielec, Jagoda
    Rosenbaum, Cara A.
    Cole, Craig E.
    Chari, Ajai
    Nam, Jennifer
    Severson, Erica
    Stephens, Leonor A.
    McDonnell, Kathryn
    Rosebeck, Shaun
    Zimmerman, Todd
    Karrison, Theodore
    Zonder, Jeffrey
    BLOOD, 2016, 128 (22)
  • [27] Melflufen and dexamethasone (dex) plus bortezomib (BTZ) or daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) (OP-104)
    Pour, Ludek
    Efebera, Yvonne
    Granell, Miquel
    Hajek, Roman
    Oriol, Albert
    Delaunay, Jacques
    Le Du, Katell
    Eveillard, Jean-Richard
    Karlin, Lionel
    Maisnar, Vladimir
    Martinez-Lopez, Joaquin
    Mateos, Maria-Victoria
    Moreb, Jan
    Ribrag, Vincent
    Richardson, Paul G.
    Straub, Jan
    Byrne, Catriona
    Jacques, Christian
    Zubair, Hanan
    Ocio, Enrique
    CANCER RESEARCH, 2019, 79 (13)
  • [28] Pomalidomide (POM), bortezomib (BORT), and dexamethasone (DEX) after 1 prior line of therapy in relapsed or refractory multiple myeloma (RRMM): a safety subanalysis of the phase 3 OPTIMISMM trial
    Weisel, Katja
    Dimopoulos, Meletios
    Oriol, Albert
    Beksac, Meral
    Schjesvold, Frederick
    Liberati, Anna Marina
    Lindsay, Jindriska
    White, Darrell
    San-Miguel, Jesus
    Moreau, Philippe
    Anderson, Larry D., Jr.
    Lorocca, Alessandra
    Robak, Pawel
    Vogel, Prisca
    Jiang, Ruiyun
    Grote, Lara
    Peluso, Teresa
    Richardson, Paul
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 166 - 166
  • [29] Dose-escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) plus low-dose dexamethasone (Dex) (CRd) in relapsed/refractory multiple myeloma (R/R MM)
    Bensinger, W.
    Wang, M.
    Orlowski, R. Z.
    Alsina, M.
    Martin, T.
    Singhal, S.
    Gabrall, N. Y.
    Vallone, M.
    Kauffman, M.
    Niesvizky, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) in patients with relapsed or relapsed/refractory multiple myeloma (MM): Preliminary results of a phase II study
    Richardson, Paul
    Jagannath, Sundaf
    Raje, Noopur
    Jakubowiak, Andrzej
    Lonial, Sagar
    Ghobrial, Irene
    Schlossman, Robert
    Mazumder, Amitabha
    Munshi, Nikhil
    Colson, Kathleen
    McKenney, Mary
    Farrell, Melissa
    Lunde, Laura
    Giove, Lawrence
    Kaster, Sarah
    Mitsiades, Constantine
    Hideshima, Teru
    Knight, Robert
    Esseltine, Dixie-Lee
    Anderson, Kenneth
    BLOOD, 2007, 110 (11) : 797A - 797A
12345